The main goal of this research is to understand the long-term safety of GD2IL18CART treatment. The study will follow patients who have already received this treatment to monitor how they respond over time. During the study, doctors will track any delayed side effects that might occur, including the possibility of infections, cancer returning, or new health problems developing.

The study involves regular check-ups to monitor patients’ health status. For younger patients, growth and development will also be monitored. The research team will collect information about the patients’ overall health and perform tests to check if the treatment cells are still present in their bodies. This long-term monitoring will help understand how the treatment affects patients over time.

The trial also investigates whether maintenance therapy with the medications vinorelbine and cyclophosphamide after initial treatment helps prevent the cancer from returning. Additionally, the study examines different approaches to radiotherapy, including whether higher doses of radiation improve outcomes for patients with tumors that cannot be surgically removed, and what radiation dose works best after surgical removal of tumors.

Patients in this study will receive chemotherapy and then, depending on their specific situation, may be assigned to different treatment groups to test these questions. Some patients will receive standard treatment while others will receive the experimental approaches being studied. Throughout the trial, patients will be monitored for how well the treatments work and any side effects that might occur.

Participants in the study will receive these medications in a specific order and combination. The study will monitor how well the treatment works and how safe it is for patients. The researchers aim to find the dose that provides the best balance between effectiveness and safety. This process is known as dose escalation, where doses are gradually increased to find the optimal level. The study will also look at how long patients remain free from cancer progression and how long the treatment response lasts.

The trial is open to children, adolescents, and adults with a specific type of Ewing Sarcoma that tests positive for a marker called GD2. The study will help determine the recommended dose for future research and treatment plans. The trial is expected to continue until 2027, with recruitment starting in 2025. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on the treatment’s effects.

The purpose of the study is to determine the appropriate dose of lutetium Lu 177 edotreotide for children, based on its safety and how it moves through the body. The study will involve giving the treatment to participants and monitoring them to see how their bodies respond. This includes checking for any side effects and measuring how the treatment is absorbed by the body. The study will also look at how effective the treatment is in reducing the size of the tumors.

Participants in the study will receive the treatment through an intravenous infusion, which means it will be given directly into a vein. The study will take place over several cycles, with regular check-ups to monitor the participants’ health and the progress of the treatment. The goal is to find the safest and most effective dose for treating these types of tumors in children. The study is expected to continue for several years to gather enough information to make informed decisions about the treatment’s use in the future.

Participants in the study will receive the medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will follow a specific schedule where patients will receive high doses of Treosulfan and Melphalan over a set period. The treatment is designed to be part of a larger strategy that includes other therapies to manage Ewing Sarcoma. The study aims to see how well patients tolerate the treatment and to measure how long they remain free from cancer progression or relapse.

Throughout the study, researchers will monitor participants for any side effects and track their overall health. The study will also look at the long-term survival of patients over a period of three years. By participating in this study, researchers hope to gather important information that could improve treatment options for people with high-risk Ewing Sarcoma in the future.

The treatment involves different combinations of these medications given either through an intravenous infusion into a vein or as oral capsules taken by mouth. Some medications are given daily while others are administered on specific days during treatment cycles that typically last several weeks. The total treatment duration may continue for up to 104 weeks depending on how well the treatment works.

Throughout the study, doctors will monitor the size of tumors using imaging scans to check if the treatment is working. They will also track any side effects and how long patients stay in the hospital. The study measures how long patients live without their disease getting worse and their overall survival time. Additionally, patients’ quality of life will be evaluated during the treatment period.

The purpose of the study is to evaluate the safety and effectiveness of adding naxitamab to the standard chemotherapy regimen for patients with refractory Ewing’s sarcoma. “Refractory” means that the cancer has not responded to previous treatments. Participants in the study will receive either the combination of naxitamab and chemotherapy or chemotherapy alone. The study will monitor the safety of the treatment by observing any side effects and will also assess how well the cancer responds to the treatment.

Throughout the study, participants will undergo regular medical examinations and laboratory tests to track their health and the progress of the cancer. The study aims to provide valuable information on whether the addition of naxitamab can improve outcomes for patients with this challenging form of cancer. The trial is expected to continue until 2028, allowing researchers to gather comprehensive data on the treatment’s long-term effects.

Participants in the study will receive one of the treatment combinations, and some may receive a placebo. The study will monitor the safety and effectiveness of these treatments over time. The trial will also look at how the body processes these medications and their impact on the participants’ quality of life. The study aims to find the best dose of these medications that can be safely given to patients.

The trial will involve regular check-ups and tests, such as MRI or CT scans, to track the progress of the treatment. Participants will be closely monitored for any side effects or changes in their condition. The study is expected to continue until November 2025, with the goal of improving treatment options for young patients with these challenging cancers.

The purpose of this study is to determine if adding Abemaciclib to the chemotherapy drugs Irinotecan and Temozolomide can provide benefits for patients whose Ewing’s Sarcoma has returned or did not respond to previous treatments. Participants in the study will receive these medications over a period of time, and their health will be monitored to see how the cancer responds to the treatment. The study aims to understand if this combination of medications can help control the disease better than the standard treatments alone.

Throughout the study, participants will be closely observed by medical professionals to ensure their safety and to track the effectiveness of the treatment. The study will help gather important information about the potential benefits of this new treatment approach for Ewing’s Sarcoma, which could lead to improved care for patients in the future.

The purpose of the study is to determine the safety and appropriate dosage of GD2IL18CART and to see how well it works in treating these cancers. Participants will receive the treatment through an intravenous infusion, which means it will be delivered directly into the bloodstream. The study will monitor participants for any side effects and measure how the cancer responds to the treatment over time. Some participants may receive a placebo, which is a substance with no active treatment, to compare the effects of the new therapy.

Throughout the study, researchers will carefully observe the participants’ health and the behavior of the cancer. The study aims to find the best dose of GD2IL18CART that is both safe and effective. Participants will be followed for a period to assess the treatment’s impact on their cancer and overall health. This trial is an important step in developing new therapies for cancers that are difficult to treat with existing methods.

The study combines two types of treatment: a medication called trabectedin (given through an intravenous infusion) and low-dose radiation therapy. Trabectedin is administered as a solution that is prepared from a powder and given through a special tube placed in a vein. The dose used in this study is 1.5 milligrams per square meter of body surface.

The main goal of this research is to determine how well tumors respond to this combination treatment, particularly in areas that receive radiation therapy. Throughout the study, researchers will monitor changes in tumor size, track how long the treatment remains effective, and assess its effects on pain levels and overall well-being. They will also carefully watch for any side effects that may occur during treatment.

Participants in the study will take lenvatinib in the form of a capsule, which is taken by mouth. The study will monitor the response of the tumors to the treatment over a period of time, specifically looking at the changes in the size of the tumors and any side effects experienced by the participants. The study aims to determine the effectiveness of lenvatinib in shrinking the tumors and improving the condition of the patients.

The study will last for several weeks, during which participants will receive regular check-ups and assessments to track their progress. The researchers will use specific criteria to evaluate the response of the tumors to the treatment, ensuring that the results are accurate and reliable. This study is an important step in finding better treatment options for young patients with these challenging types of cancer.

The purpose of the study is to see if the new treatment approach can increase the time patients remain free from cancer events compared to the standard treatment alone. The study will also look at whether a higher dose of radiation therapy is as safe as the standard dose in terms of skin side effects. Patients will receive a series of treatment cycles, and some may receive a placebo, which is a substance with no active medication, to compare the effects of the new treatment.

Throughout the study, patients will be monitored for their overall survival, which means the length of time they live after starting the treatment, as well as their quality of life. The study will also explore other factors like the biology of Ewing sarcoma and how quickly the disease is diagnosed. The trial is expected to continue until 2031, with the goal of improving treatment outcomes for patients with this type of cancer.

Participants in the study will receive the combination of regorafenib and chemotherapy. The study will monitor how the body responds to the treatment and any side effects that may occur. The study will also look at how the cancer responds to the treatment, including whether it shrinks or stops growing. The study will last for several years, and participants will be closely monitored throughout the process to ensure their safety and to gather important information about the treatment’s effectiveness.

The study aims to improve the treatment options for patients with Ewing sarcoma by determining the most effective way to use regorafenib in combination with chemotherapy. This research could potentially lead to better outcomes for patients with this challenging form of cancer. Participants will be contributing to important research that may help future patients with Ewing sarcoma.

The purpose of the study is to find out which combination of these treatments is safe and effective for young patients with these challenging types of cancer. In the first stage of the study, researchers will determine which of the three chemotherapy regimens is safe to use with Nivolumab. The regimens being tested are: Cyclophosphamide and Vinblastine; Capecitabine alone; and a combination of Cyclophosphamide, Vinblastine, and Capecitabine. In the second stage, the study will focus on the most promising regimen from the first stage, with or without Nivolumab, to see how well it works in preventing the cancer from getting worse.

Participants in the study will receive their treatments either through an intravenous method, which means the medication is given directly into a vein, or orally, which means taking the medication by mouth. The study will monitor the participants over time to assess the safety of the treatments and their effectiveness in controlling the cancer. The study aims to provide valuable information that could lead to better treatment options for children and teenagers facing these difficult cancers.

The treatment being tested in this study is an IPX vaccine, which is an emulsion for injection. This vaccine is made up of specific proteins, including PERVI-FUS, PERVI-NEO, and 11902A. The purpose of the study is to see if this vaccine can help the body’s immune system, particularly T-cells, to respond to the cancer. T-cells are a type of white blood cell that play a crucial role in the immune response. The study will compare the effects of the vaccine to a placebo, which is a substance with no active ingredients.

Participants in the study will receive the vaccine over a period of time, with the maximum treatment period being 113 days. The study will monitor the participants’ immune response to the vaccine, as well as their overall health and quality of life during the treatment. The primary goal is to determine if the vaccine can successfully induce a T-cell response without causing unacceptable side effects. The study will also look at other factors, such as the participants’ event-free survival and overall survival at 180 days after the start of the study.

The purpose of this study is to see how well these medications work together in stopping the progression of these sarcomas over a period of six months. Participants in the study will receive pembrolizumab as an infusion, which means it is given directly into the bloodstream through a vein, and cabozantinib as a tablet taken by mouth. The study will last for up to 24 months, during which time the participants will be monitored regularly to assess the effects of the treatment on their cancer.

Throughout the study, doctors will use imaging techniques like MRI or CT scans to check the size of the tumors and see if they are responding to the treatment. The study aims to determine if the combination of pembrolizumab and cabozantinib can help control the disease and improve the quality of life for patients with these advanced sarcomas. Participants will also be monitored for any side effects from the medications to ensure their safety during the trial.

Participants in the study will receive either the GnRHa treatment or a placebo, which is a substance with no active medication. The GnRHa treatment being studied is called Pamorelin, which is given as an injection. There are two different doses of Pamorelin being used in the study: 3.75 mg and 11.25 mg. The study will follow participants for several years to monitor their ovarian reserve and other health factors. This includes measuring levels of a hormone called Anti-Müllerian Hormone (AMH), which helps indicate the number of eggs left in the ovaries, at various points after the end of chemotherapy.

Throughout the study, participants will have regular check-ups to assess their ovarian reserve and overall health. This will involve tests like ultrasounds and blood tests to measure hormone levels. The study aims to provide valuable information on how GnRHa might help preserve fertility in young women and teenagers undergoing cancer treatment. By understanding the effects of this treatment, researchers hope to improve future care for patients facing similar challenges.